APP and Alzheimer disease: The results indicated that early subcutaneous injection of GA in APP/PS1 mice induced therapeutic benefits against AD, including expanding the frequency of peripheral Tregs, reducing the activation of microglia, and regulating the neuroinflammation by increasing the level of anti-inflammatory cytokines, which eventually delayed the impairment of cognitive function imposed by amyloid accumulation.